In this study, we discovered a correlation between KRAS genotype and in vivo response to the proteasome inhibitor ixazomib in a heterogeneous group of 14 NSCLC and 6 colon xenograft models. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.